Abstract：
The coronavirus disease-19 (COVID-19) vaccine efficacy and immunogenicity in the immunocompetent population are well established. However, in solid organ transplant (SOT) recipients, because of their use of immunosuppressive medication, the immunogenicity of these severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines remains suboptimal. Both BNT162b2 and mRNA1273 have been used for some time, but their immunogenicity has not been directly compared in this immunocompromised patient group. We performed a post-hoc analysis of a previous prospective cohort study. The inclusion criteria were adult SOT recipients with active grafts at least 1 month after SOT. After giving consent, participants chose to receive either BNT162b2 or mRNA1273 vaccine. Anti-spike-protein-S antibody against SARS-CoV-2 was measured. Propensity scores were calculated via logistic regression to transform the probability of having received either BNT162b2 or mRNA1273 vaccine, and a model was developed. We enrolled 623 SOT recipients. In the propensity score-matched analysis, 100 recipients were selected for BNT162b2 and 100 for mRNA1273. SARS-CoV-2 anti-spike protein antibody positivity with BNT162b2 versus mRNA1273 at 3 weeks after the first dose, 1 month after the second dose, 3 months after the second dose, and 6 months after the second dose were 10% versus 19% (P = .07), 51% versus 58% (P = .30), 74% versus 88% (P = .01), and 78% versus 87% (P = .13), respectively. We conducted a propensity score-matched comparison of BNT162b2 and mRNA1273 vaccines as the primary series of COVID-19 vaccines in SOT recipients. We found significantly better immunogenicity with the mRNA1273 vaccine than with BNT162b2.
摘要：
冠状病毒病-19(COVID-19)疫苗在免疫活性人群中的功效和免疫原性是公认的。然而,在实体器官移植（SOT）接受者中，因为他们使用了免疫抑制药物，这些严重急性呼吸综合征冠状病毒2(SARS-CoV-2)疫苗的免疫原性仍然不理想.BNT162b2和mRNA1273已经使用了一段时间，但是在这个免疫功能低下的患者组中，它们的免疫原性尚未直接比较。我们对先前的前瞻性队列研究进行了事后分析。纳入标准为SOT后至少1个月有活性移植物的成人SOT接受者。同意后，参与者选择接受BNT162b2或mRNA1273疫苗.测定抗SARS-CoV-2的抗刺突蛋白-S抗体。通过逻辑回归计算倾向得分，以转换接受BNT162b2或mRNA1273疫苗的概率。并开发了一个模型。我们注册了623名SOT收件人。在倾向得分匹配分析中，对于BNT162b2选择100个接受者,对于mRNA1273选择100个接受者。首次给药后3周，BNT162b2与mRNA1273的SARS-CoV-2抗刺蛋白抗体阳性，第二次给药后1个月，第二次给药后3个月，第二次给药后6个月为10%对19%(P=0.07)，51%对58%（P=0.30），74%对88%（P=0.01），78%对87%(P=0.13)，分别。我们对作为SOT接受者主要系列COVID-19疫苗的BNT162b2和mRNA1273疫苗进行了倾向评分匹配比较。我们发现mRNA1273疫苗的免疫原性明显优于BNT162b2。
